Predictive Oncology Stock Performance
| POAI Stock | USD 1.63 0.13 7.39% |
The company holds a Beta of 1.42, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Predictive Oncology will likely underperform. Predictive Oncology has an expected return of -0.77%. Please make sure to check Predictive Oncology skewness, and the relationship between the treynor ratio and rate of daily change , to decide if Predictive Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Predictive Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:20 | Dividend Date 2019-10-29 | Last Split Date 2023-04-24 |
1 | Predictive Oncology Inc. Short Interest Down 8.3 percent in January - AmericanBankingNEWS | 02/15/2024 |
2 | Is Predictive Oncology Inc a Stock to Watch After Gaining 4.55 percent This Week - InvestorsObserver | 03/14/2024 |
3 | Acquisition by Chung-welch Nancy of 9924 shares of Predictive Oncology subject to Rule 16b-3 | 03/22/2024 |
4 | Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update | 03/28/2024 |
5 | Predictive Oncology Inc. Q4 2023 Earnings Call Transcript - Seeking Alpha | 04/01/2024 |
6 | Acquisition by Chung-welch Nancy of 2353 shares of Predictive Oncology subject to Rule 16b-3 | 04/05/2024 |
7 | Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting | 04/24/2024 |
8 | Predictive Oncology stock rallies 30 percent post-market on vaccine collaboration | 04/30/2024 |
9 | Predictive Oncology Inc. Reports Q3 Loss, Misses Revenue Estimates - Yahoo New Zealand News | 05/07/2024 |
10 | Predictive Oncology to Report First Quarter 2024 Financial Results onWednesday, May 15, 2024 | 05/10/2024 |
| Begin Period Cash Flow | 22.1 M |
Predictive |
Predictive Oncology Relative Risk vs. Return Landscape
If you would invest 304.00 in Predictive Oncology on February 12, 2024 and sell it today you would lose (141.00) from holding Predictive Oncology or give up 46.38% of portfolio value over 90 days. Predictive Oncology is currently does not generate positive expected returns and assumes 6.3579% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Predictive, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Predictive Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Predictive Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Predictive Oncology, and traders can use it to determine the average amount a Predictive Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1218
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | POAI |
Estimated Market Risk
| 6.36 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.77 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Predictive Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Predictive Oncology by adding Predictive Oncology to a well-diversified portfolio.
Predictive Oncology Fundamentals Growth
Predictive Stock prices reflect investors' perceptions of the future prospects and financial health of Predictive Oncology, and Predictive Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Predictive Stock performance.
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | (10.46) % | ||||
| Current Valuation | 751.4 K | ||||
| Shares Outstanding | 4.06 M | ||||
| Price To Book | 0.86 X | ||||
| Price To Sales | 4.02 X | ||||
| Revenue | 1.78 M | ||||
| Gross Profit | 1 M | ||||
| EBITDA | (13.18 M) | ||||
| Net Income | (13.98 M) | ||||
| Cash And Equivalents | 25.39 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 2.86 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | 2.04 X | ||||
| Cash Flow From Operations | (13.19 M) | ||||
| Earnings Per Share | (3.48) X | ||||
| Market Capitalization | 6.62 M | ||||
| Total Asset | 14.42 M | ||||
| Retained Earnings | (167.76 M) | ||||
| Working Capital | 6.13 M | ||||
About Predictive Oncology Performance
To evaluate Predictive Oncology Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Predictive Oncology generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Predictive Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Predictive Oncology market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Predictive's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 133.99 | 127.29 | |
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (1.33) | (1.40) | |
| Return On Assets | (0.97) | (1.02) | |
| Return On Equity | (1.69) | (1.78) |
Things to note about Predictive Oncology performance evaluation
Checking the ongoing alerts about Predictive Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Predictive Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Predictive Oncology generated a negative expected return over the last 90 days | |
| Predictive Oncology has high historical volatility and very poor performance | |
| Predictive Oncology may become a speculative penny stock | |
| Predictive Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.78 M. Net Loss for the year was (13.98 M) with profit before overhead, payroll, taxes, and interest of 1 M. | |
| Predictive Oncology currently holds about 25.39 M in cash with (13.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Predictive Oncology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Predictive Oncology to Report First Quarter 2024 Financial Results onWednesday, May 15, 2024 |
- Analyzing Predictive Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Predictive Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Predictive Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Predictive Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Predictive Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Predictive Oncology's stock. These opinions can provide insight into Predictive Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.Note that the Predictive Oncology information on this page should be used as a complementary analysis to other Predictive Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Predictive Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.48) | Revenue Per Share 0.443 | Quarterly Revenue Growth (0.08) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.